


Ursachen der Mitralstenose


Verteilung der Ursachen nach Alter



FR 49Hz
16cm

2D
57%
C 50
P Low
HGen

M3



JPEG


67 bpm



FR 43Hz
19cm

2D
57%
C 50
P Low
HGen

M3



JPEG

68 bpm



FR 14Hz
19cm

2D
58%
C 50
P Low
HGen

CF
66%
2.5MHz
WF High
Med



A

M3 M4
+61.6



JPEG

69 bpm

Adult Echo

X7-2t

37Hz

12cm

Full Volume

2D / 3D

% 54 / 51

C 50 / 30

Gen

3D Beats 4Q



TIS0.1 MI 0.3

M4



PAT T: 37.0C

TEE T: 40.0C

Delay 0ms

104 bpm

Adult Echo

X7-2t

37Hz

12cm

Full Volume

2D / 3D

% 54 / 51

C 50 / 30


Gen

3D Beats 4Q



TIS0.1 MI 0.3

M4



PAT T: 37.0C

TEE T: 40.0C

Delay 0ms

104 bpm

Adult Echo

X7-2t

37Hz

12cm

Full Volume

2D / 3D

% 54 / 51





C 50 / 30

Gen

18/12/2015 13:39:06

TIS0.1 MI 0.3

3D Beats 4Q




FR 14Hz
19cm



2D
57%
C 50
P Low
HGen
CF
66%
2.5MHz
WF High
Med

CW
50%
1.8MHz
WF 225Hz


M3 M4
+61.6
-61.6
cm/s



Hämodynamik der Mitralstenose



Folgen der Mitralkstenose




Mitralstenose und kardiale Funktion

Linker Vorhof:


Progressive Dilatation
Atriale Arrhythmien
Atriale Thromben
Embolische Ereignisse

Sekundäre pulmonale Hypertonie:

Hämoptyse ('Herzfehlerzellen')
Lungenödem
Rechtsherzbelastung



Mitralstenose



1: paukend

2: normal

Mesodiastolisches Geräusch, Decrescendo, rumpelnd

Ausstrahlung in Axilla, v. a. in Linksseitenlage

Häufig mit protodiastolischem Click (MOET)

Häufig kombiniert mit Mitralinsuffizienz

Palpation:

Herz: Eventuell Zeichen der Rechtsherzbelastung

Puls: Häufig unregelmässig wegen VHF

Arterieller Blutdruck:

Normale Amplitude



EKG:

Sinusrhythmus (VHF); Vorhofbelastung; Repolarisationsstörung

Mitralstenose

Untersuchung von Patienten mit MS





Auskultationsort	Schematische phonokardiografische Darstellung	Key point
 p.m.: Herzspitze		Herztöne: paukender 1. HT und MÖT bei MS, evtl. TÖT bei TS Extratöne: keine Herzgeräusche: tieffrequentes, diastolisches Decrescendo-geräusch, evtl. Präsysstolikum

Kombiniertes Mitralvitium

Untersuchung von Patienten mit MI/MS



Auskultationsort	Schematische phonokardiografische Darstellung	Key point
 p.m.: Herzspitze	 1. HT 2. HT 1. HT	Herztöne: paukender 1. HT Extratöne: keine Herzgeräusche: <i>Systole</i>: hochfrequentes, holosystolisches bandförmiges Geräusch <i>Diastole</i>: tieffrequentes, mesodiastolisches Decrescendo


Quantifizierung der Mitralstenose

	Mitral Stenosis		
	Mild	Moderate	Severe
Mean gradient (mm Hg)*	Less than 5	5–10	Greater than 10
Pulmonary artery systolic pressure (mm Hg)	Less than 30	30–50	Greater than 50
Valve area (cm ²)	Greater than 1.5	1.0–1.5	Less than 1.0


<i>Grade</i>	<i>Mobility</i>	<i>Subvalvar thickening</i>	<i>Thickening</i>	<i>Calcification</i>
1	Highly mobile valve with only leaflet tips restricted	Minimal thickening just below the mitral leaflets	Leaflets near normal in thickness (4–5 mm)	A single area of increased echo brightness
2	Leaflet mid and base portions have normal mobility	Thickening of chordal structures extending up to one third of the chordal length	Mid-leaflets normal, considerable thickening of margins (5–8 mm)	Scattered areas of brightness confined to leaflet margins
3	Valve continues to move forward in diastole, mainly from the base	Thickening extending to the distal third of the chords	Thickening extending through the entire leaflet (5–8 mm)	Brightness extending into the mid-portion of the leaflets
4	No or minimal forward movement of the leaflets in diastole	Extensive thickening and shortening of all chordal structures extending down to the papillary muscles	Considerable thickening of all leaflet tissue (> 8–10 mm)	Extensive brightness throughout much of the leaflet tissue

The total echocardiographic score was derived from an analysis of mitral leaflet mobility, valvar and subvalvar thickening, and calcification which were graded from 0 to 4 according to the above criteria. This gave a total score of 0 to 16.

Therapie der schweren Mitralstenose



Mitralklappen-Valvuloplastie



Contra-indications

Mitral valve area $>1.5 \text{ cm}^{2a}$

Left atrial thrombus





More than mild mitral regurgitation

Severe or bi-commissural calcification


Absence of commissural fusion

Severe concomitant aortic valve disease, or severe combined tricuspid stenosis and regurgitation requiring surgery

Concomitant CAD requiring bypass surgery





Mitralklappen-Kommissurotomie




Mitralstenose und medikamentöse Therapie

- **Betablocker, Calciumantagonisten**
→ **Verlangsamung der HF**
- **Diuretika, Nitrate**
→ **Vorlastsenkung**
- **Antikoagulation**
 - **VHF**
 - **St. n. Embolie**
 - **Thrombus /Spontankontrast im LA**
 - **LA-Dilatation (>60 ml/m²)**









Klappenerkrankungen

Prävalenz



Prognose



**Rechtsseitige Klappenerkrankungen:
0.8% aller nativen Klappenerkrankungen**

Tricuspidalklappenerkrankungen

Tricuspidalinsuffizienz

Tricuspidalstenose

Ursachen der Tricuspidalinsuffizienz

Ursachen:

Kongenitale Herzerkrankungen

Sekundäre Tricuspidalinsuffizienz

Pulmonale Hypertonie

Endokarditis

Rheumatisches Fieber

Medikamentöse Valvulopathie

Carcinoid Syndrom



Ursachen der Tricuspidalinsuffizienz

1. Primary tricuspid regurgitation
 - (A) Congenital
 - Tricuspid valve prolapse
 - Ebstein's anomaly
 - Tricuspid valve dysplasia (grades I-III)
 - Abnormal number of leaflets
 - Atrioventricular channel
 - Cleft of a tricuspid leaflet
 - Left sided tricuspid valve in congenitally corrected transposition of the great arteries
 - Pulmonary atresia with intact ventricular septum
 - Short tendinous chords
 - Aberrant tendinous chords with tethering of the tricuspid leaflets
 - (B) Acquired
 - Endocarditis
 - Rheumatic valve disease
 - Right ventricular infarction
 - Heart transplantation
 - Carcinoid (or other tumours)
 - Trauma
 - Rheumatic arthritis
 - Radiation therapy
 - Papillary muscle dysfunction
 - Hypereosinophilic syndrome
 - Thyrotoxicosis
 - Anorectic drugs
2. Secondary tricuspid regurgitation
3. Physiological tricuspid regurgitation


Tricuspidalinsuffizienz

Untersuchung von Patienten mit TI



Auskultationsort	Schematische phonokardiografische Darstellung	Key point
 p.m.: Herzspitze	 1. HT 2. HT 1. HT 3. HT	Herztöne: 1. HT leise oder fehlend, 2. HT breit gespalten Extratöne: 3. HT Herzgeräusche: hochfrequentes, holosystolisches, band- förmiges Geräusch

Therapie der schweren Tricuspidalinsuffizienz



Ursachen der Tricuspidalstenose

Ursachen:

Kongenitale Herzerkrankungen

Rheumatisches Fieber



Medikamentöse Valvulopathie

Carcinoid Syndrom

Häufig kombiniert mit Tricuspidalinsuffizienz

Untersuchung von Patienten mit TS



Auskultationsort	Schematische phonokardiografische Darstellung	Key point
 p.m.: Herzspitze	 MÖT (bzw. TÖT) 1. HT 2. HT 1. HT	Herztöne: paukender 1. HT und MÖT bei MS, evtl. TÖT bei TS Extratöne: keine Herzgeräusche: tieffrequentes, diastolisches Decrescendo- geräusch, evtl. Präsysstolikum

Tricuspidalstenose

**Patienten mit Tricuspidalstenose sollten
an einem Zentrumsspital behandelt werden**

Echokardiographie bei Klappenerkrankungen

Frequenz der Echokardiographien in asymptomatischen Patienten with Klappenerkrankungen und normaler linksventrikulärer Function

Stage	Valve Lesion			
Stage	Aortic Stenosis*	Aortic Regurgitation	Mitral Stenosis	Mitral Regurgitation
Progressive (stage B)	Every 3–5 y (mild severity $V_{\max}$ 2.0–2.9 m/s) Every 1–2 y (moderate severity $V_{\max}$ 3.0–3.9 m/s)	Every 3–5 y (mild severity) Every 1–2 y (moderate severity)	Every 3–5 y (MVA >1.5 cm ²)	Every 3–5 y (mild severity) Every 1–2 y (moderate severity)
Severe (stage C)	Every 6–12 mo ($V_{\max} \geq 4$ m/s)	Every 6–12 mo Dilating LV: more frequently	Every 1–2 y (MVA 1.0–1.5 cm ²) Once every year (MVA <1.0 cm ²)	Every 6–12 mo Dilating LV: more frequently

Patients with mixed valve disease may require serial evaluations at intervals earlier than recommended for single valve lesions.

*With normal stroke volume.

LV indicates left ventricle; MVA, mitral valve area; VHD, valvular heart disease; and $V_{\max}$, maximum velocity.

